- Trials with a EudraCT protocol (1)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1 result(s) found for: 2010-021259-22.
Displaying page 1 of 1.
EudraCT Number: 2010-021259-22 | Sponsor Protocol Number: TRX4_DM_008_WW_10 | Start Date*: 2010-12-15 | |||||||||||
Sponsor Name:TolerX, Inc. | |||||||||||||
Full Title: DEFEND-1 Long Term Follow Up: Durable-Response Therapy Evaluation for Early or New Onset Type 1 Diabetes Extension Study | |||||||||||||
Medical condition: Otelixizumab iis being developed for the treatment of patients with autoimmune T1DM with residual beta cell function (RBCF), for the purpose of preserving RBCF in this patient population. Currently... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
